GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » EBIT

Vidac Pharma Holding (STU:T9G) EBIT : €-1.37 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding EBIT?

Vidac Pharma Holding's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was €-0.50 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €-1.37 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vidac Pharma Holding's annualized ROC % for the quarter that ended in Jun. 2024 was -266.13%. Vidac Pharma Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -28,514.29%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vidac Pharma Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -4.94%.

Vidac Pharma Holding EBIT Historical Data

The historical data trend for Vidac Pharma Holding's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vidac Pharma Holding EBIT Chart

Vidac Pharma Holding Annual Data
Trend Dec21 Dec22 Dec23
EBIT
- -0.70 -1.41

Vidac Pharma Holding Semi-Annual Data
Jun22 Dec22 Jun23 Dec23 Jun24
EBIT -0.25 -0.45 -0.54 -0.87 -0.50

Competitive Comparison of Vidac Pharma Holding's EBIT

For the Biotechnology subindustry, Vidac Pharma Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vidac Pharma Holding's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vidac Pharma Holding's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vidac Pharma Holding's EV-to-EBIT falls into.


Vidac Pharma Holding EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vidac Pharma Holding  (STU:T9G) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vidac Pharma Holding's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-0.998 * ( 1 - 0% )/( (0.21 + 0.54)/ 2 )
=-0.998/0.375
=-266.13 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.138 - 0.809 - ( 0.07 - max(0, 1.016 - 0.135+0.07))
=0.21

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.109 - 0.71 - ( 0.083 - max(0, 1.246 - 0.105+0.083))
=0.54

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Vidac Pharma Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.998/( ( (0.003 + max(-0.786, 0)) + (0.004 + max(-0.894, 0)) )/ 2 )
=-0.998/( ( 0.003 + 0.004 )/ 2 )
=-0.998/0.0035
=-28,514.29 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.063 + 0 + 0.002) - (0.809 + 0 + 0.042)
=-0.786

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.002 + 0 + 0.02) - (0.71 + 0 + 0.206)
=-0.894

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vidac Pharma Holding's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-1.368/27.688
=-4.94 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vidac Pharma Holding EBIT Related Terms

Thank you for viewing the detailed overview of Vidac Pharma Holding's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Vidac Pharma Holding Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » EBIT
Comparable Companies
XTER:MDG1 XTER:HPHA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270 SMMT UTHR INSM XKRX:196170 RPRX OCSE:GMAB INCY HKSE:02269
Traded in Other Exchanges
N/A
Address
Wenlock Road, 20-22, London, GBR, N1 7GU
Website
https://www.vidacpharma.com
Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines